Monitor prescription trends for ZORYVE over the next 2-3 quarters to assess whether the celebrity endorsement campaign drives measurable market share gains. No immediate financial catalyst.
Price Chart
Executive Summary
Arcutis Biotherapeutics announced a celebrity endorsement partnership with Simone Biles to launch the 'Skin to Believe In' awareness campaign for ZORYVE (roflumilast) foam and cream. The campaign targets the ~36 million Americans with seborrheic dermatitis and eczema, aiming to drive patient awareness and physician conversations. This is a marketing initiative with no financial terms disclosed, and while it may boost brand visibility, it does not change the underlying commercial trajectory or pipeline.
Key Facts
- Simone Biles partnered with Arcutis for the 'Skin to Believe In' awareness campaign targeting seborrheic dermatitis and eczema patients.
- ZORYVE is the #1 prescribed branded topical therapy across three inflammatory skin conditions combined (seborrheic dermatitis, eczema, plaque psoriasis).
- Campaign targets approximately 36 million Americans with inflammatory skin conditions.
- No financial terms of the partnership or campaign budget were disclosed.
- ZORYVE foam 0.3% is approved for seborrheic dermatitis (ages 9+); ZORYVE cream 0.15% for atopic dermatitis (ages 6+).
Financial Impact
No financial terms disclosed; campaign is a marketing expense with uncertain ROI.
Risk Factors
- Campaign may not translate into meaningful prescription growth or revenue acceleration.
- Competition from other topical therapies for seborrheic dermatitis and eczema.
- Celebrity endorsement costs could pressure near-term margins if not offset by revenue.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3370989 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | Press Release | $32.20 | awaiting T+20 | — | $31.76 (−1.37%) |
Oct 5, 2026 21d ago | SC 13G/A | $25.15 | awaiting T+20 | — | $31.76 (+26.28%) |
Sep 29, 2026 27d ago | Press Release | $26.75 | awaiting T+20 | — | $31.76 (+18.73%) |
Sep 18, 2026 5w ago | Insider Cluster | $25.96 $31.89 | ▲ +22.84% | ▲ +23.75% | $31.76 (+22.34%) |
Sep 17, 2026 5w ago | Insider Cluster | $25.38 $28.82 | ▲ +13.55% | ▲ +13.35% | $31.76 (+25.14%) |
Aug 24, 2026 8w ago | Insider Cluster | $24.86 $26.38 | ▲ +6.11% | ▲ +5.87% | $31.76 (+27.76%) |
Aug 21, 2026 9w ago | Insider Cluster | $24.78 $27.78 | ▲ +12.11% | ▲ +10.81% | $31.76 (+28.17%) |
Aug 19, 2026 9w ago | Insider Cluster | $25.35 $25.38 | ▲ +0.12% | ▲ +0.12% | $31.76 (+25.29%) |
Aug 11, 2026 10w ago | 144 | $26.28 $23.38 | ▼ −11.04% | ▼ −9.14% | $31.76 (+20.85%) |
Aug 5, 2026 11w ago | Insider Cluster | $26.43 $23.66 | ▼ −10.48% | ▼ −11.08% | $31.76 (+20.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers